Clinical trial
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for…
NCT00146913 · Hospices Civils de Lyon, Other · Unknown status
Key facts
| NCT number | NCT00146913 |
|---|---|
| Title | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year |
| Official title | A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year |
| Lead sponsor | Hospices Civils de Lyon, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib mesylate 600mg/day, Peg-Interféron at 90 microg/week |
| Enrollment | 30 |
| Start date | Mar 1, 2004 |
| First posted | Sep 7, 2005 |
| Last update posted | Apr 27, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: